Recce Pharmaceuticals Ltd (RCE:ASX)


right-arrow Created with Sketch. 0 (0%)
MCAP $166.8M
Last trade 16.10pm 24/09/2021 20mins delayed

Latest Announcements

31/08/2021RCERecce Pharmaceuticals Ltd
31/08/2021RCERecce Pharmaceuticals Ltd
31/08/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
16/08/2021RCERecce Pharmaceuticals Ltd
11/08/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
30/07/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd
27/07/2021RCERecce Pharmaceuticals Ltd
22/07/2021 Price SensitivePSRCERecce Pharmaceuticals Ltd

Company Overview

Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The Company pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.

RCE in the news

Recce Pharmaceuticals (RCE) receives a grant of $50,000 through the Australian Government’s…
Recce Pharmaceuticals (RCE) secures a US patent for its antibiotic product RECCE…
Recce Pharmaceuticals (RCE) has been granted a patent from the Chinese Patent…
A recent study finds Recce Pharmaceutical’s (RCE) R327 candidate to demonstrate “outstanding…

Search Previous Announcements